Apyx Medical Corporation has announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AYON Body Contouring System. This marks a significant milestone as AYON becomes the first FDA-cleared all-in-one platform specifically designed for the aesthetic surgical suite. The system integrates multiple technologies for precision and versatility, including fat removal, tissue contraction, and electrosurgical capabilities. Apyx Medical plans to commercially launch AYON to key opinion leader surgeons in critical geographies during the second half of 2025. This development is set to revolutionize body contouring and enhance surgical outcomes for patients, particularly those experiencing rapid weight loss and seeking solutions for loose skin.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.